Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 14, 2009

Roche Gains Access to Cerep’s Pharmacology and ADME Database

  • Roche has inked a deal to use Cerep’s BioPrint®, a homogenous pharmacology and ADME database. The BioPrint database is composed of three main data sets: chemical descriptors (structures and chemical information, 2-D and 3-D descriptors), in vitro profiles, and in vivo effects of tested compound.

    Cerep will also generate new BioPrint® data on Roche compounds for Roche’s exclusive use. Additionally, the companies will collaborate on further development of BioPrint® and related pharmaco-informatics tools aimed at predicting as early as possible adverse drug reactions that could lead to clinical trial failures. 

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »